See also this year's filing and all EDGAR filings for this company.
PDF Report 0001426332_2021_NGM_BIOPHARMACEUTICALS_INC.pdf
Logs
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'PROVECTUS BIOPHARMACEUTICALS INC.', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'REGENERX BIOPHARMACEUTICALS INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001426332, NGM BIOPHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 308,426,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 14,526,000 |
| 3 | remainder_Assets | 6,091,000 |
| 4 | LiabilitiesCurrent | 42,583,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 6,417,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 27,229,000 |
| 9 | ResearchAndDevelopmentExpense | 163,972,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 87,368,000 |
| 12 | remainder_NetIncome | 1,346,000 |
| 13 | remainder_ComprehensiveNetIncome | -21,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 329,043,000 |
| 1 | Liabilities | 49,000,000 |
| 2 | Expenses | 191,201,000 |
| 3 | Revenues | 87,368,000 |
| 4 | StockholdersEquity | 280,043,000 |
| 5 | NetIncome | -102,487,000 |
| 6 | ComprehensiveNetIncome | -102,497,500 |
| 7 | BaseVar | 328,989,500 |
| 8 | EconomicCapitalRatio | 2.01 |
Edgar->Model Mapping
Feature Distribution
Change over Time
